Biomarkers /
PARP2
Overview
PARP2 is altered in 0.89% of all cancers with colon adenocarcinoma, invasive breast carcinoma, and prostate adenocarcinoma having the greatest prevalence of alterations [3].
The most common alterations in PARP2 are PARP2 Mutation (0.89%), PARP2 D95A (0.30%), PARP2 G442V (0.30%), and PARP2 R41T (0.30%) [3].
Clinical Trials
Significance of PARP2 in Diseases
References
1. Hart R and Prlic A. Universal Transcript Archive Repository. Version uta_20180821. San Francisco CA: Github;2015. https://github.com/biocommons/uta
2. The UniProt Consortium. UniProt: a worldwide hub of protein knowledge. Nucleic Acids Research. 2019;47:D506-D515.
3. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.
4. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.